- Home
- NRGV vs GLUE Comparison
NRGV vs GLUE Comparison
Compare NRGV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRGV | GLUE |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.7M | 1.2B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRGV | GLUE |
|---|---|---|
| Price | $3.49 | $15.39 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 3.8M | 883.3K |
| Earning Date | 03-17-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $203,671,000.00 | $123,672,000.00 |
| Revenue This Year | $23.55 | N/A |
| Revenue Next Year | $28.25 | $13.49 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | ★ 340.86 | 63.54 |
| 52 Week Low | $0.60 | $3.50 |
| 52 Week High | $6.35 | $25.77 |
Technical Indicators
Market Signals| Indicator | NRGV | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 37.50 |
| Support Level | $2.95 | $14.93 |
| Resistance Level | $3.54 | $16.66 |
| Average True Range (ATR) | 0.30 | 0.86 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 42.46 | 32.61 |
Price Performance
Historical ComparisonAbout NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).